Pieris AG announced today the initiation of a Phase I clinical trial with PRS-080, an anti-hepcidin Anticalin ® therapeutic protein designed to treat anemia.
Pieris AG announced today the initiation of a Phase I clinical trial with PRS-080, an anti-hepcidin Anticalin ® therapeutic protein designed to treat anemia.